Pfizer has signed a definitive agreement to acquire Metsera, a privately held clinical-stage biotechnology company focused on obesity and cardiometabolic therapies, in a transaction valued at approximately $4.9 billion in cash. The deal includes additional milestone-based payments that could bring the total value to $7.3 billion, according to a joint announcement issued on September 22.
Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera for $47.50 per share in cash at closing. An additional $22.50 per share may be payable to Metsera shareholders if the company achieves three regulatory and clinical development milestones. These include the initiation of a Phase 3 clinical trial for a combination therapy, as well as U.S. Food and Drug Administration (FDA) approvals for Metsera’s lead candidates.
Metsera was founded in 2022 and is headquartered in New York. The company’s portfolio includes multiple investigational therapies targeting obesity and related metabolic conditions. Its lead asset, MET-097i, is a long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist currently in Phase 2 clinical trials. The compound is being tested in both weekly and monthly dosing formats.
Metsera is also developing MET-233i, an amylin analog currently in Phase 1 clinical development. Both assets are being studied individually and in combination. In addition to injectable candidates, Metsera is advancing oral GLP-1 receptor agonists that are expected to enter clinical trials soon. The company is also conducting preclinical research into nutrient-stimulated hormone therapies that aim to address the underlying biology of obesity and metabolic diseases.
Metsera brings clinical and preclinical obesity drug assets
According to Metsera, its approach seeks to expand the treatment landscape with differentiated therapies that could provide broader options for patients. The transaction has been unanimously approved by the boards of directors of both companies. Subject to customary closing conditions, including regulatory clearances and approval by Metsera shareholders, the deal is expected to close in the fourth quarter of 2025.
Pfizer announced earlier this year that it would discontinue development of its own oral obesity drug candidate danuglipron following adverse events observed in clinical trials. The acquisition of Metsera marks a significant move by the company to re-enter the obesity drug market through externally developed assets. The obesity treatment sector has experienced accelerated growth, driven by rising global prevalence of obesity and increasing demand for new therapeutic options.
Pharmaceutical companies have been expanding investment in the category, particularly in GLP-1 receptor agonists, which have demonstrated clinically significant weight loss and metabolic benefits. Shares of Metsera surged approximately 60 percent following the announcement of the acquisition. Pfizer’s stock also showed modest gains during intraday trading.
Pfizer continues pipeline expansion via strategic buyouts
The company stated that the acquisition is aligned with its capital allocation priorities and will be financed through existing cash reserves. Metsera employs a workforce of approximately 100 employees across research, clinical, and corporate functions. Following the closing of the transaction, the company will operate as a wholly owned subsidiary of Pfizer.
The integration process and operational alignment will be conducted in accordance with regulatory guidelines and corporate governance standards. The acquisition represents one of Pfizer’s largest transactions in recent years in the metabolic and endocrine disease space. The company continues to pursue targeted acquisitions and partnerships that complement its pipeline and commercial portfolio. – By Content Syndication Services.